Akoya Biosciences Ownership
| AKYA Stock | USD 1.68 0.06 3.70% |
Shares in Circulation | First Issued 2020-03-31 | Previous Quarter 49.5 M | Current Value 49.6 M | Avarage Shares Outstanding 39.4 M | Quarterly Volatility 7.5 M |
Akoya |
Akoya Stock Ownership Analysis
About 67.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.16. Akoya Biosciences had not issued any dividends in recent years. Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts. Akoya Biosciences operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 319 people. For more info on Akoya Biosciences please contact Brian McKelligon at 855 896 8401 or go to https://www.akoyabio.com.Besides selling stocks to institutional investors, Akoya Biosciences also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Akoya Biosciences' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Akoya Biosciences' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Akoya Biosciences Quarterly Liabilities And Stockholders Equity |
|
About 67.0% of Akoya Biosciences are currently held by insiders. Unlike Akoya Biosciences' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Akoya Biosciences' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Akoya Biosciences' insider trades
Akoya Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Akoya Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Akoya Biosciences backward and forwards among themselves. Akoya Biosciences' institutional investor refers to the entity that pools money to purchase Akoya Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Osterweis Capital Management Inc | 2024-12-31 | 126.1 K | Schonfeld Strategic Advisors Llc | 2024-12-31 | 122 K | Bridgeway Capital Management, Llc | 2024-12-31 | 105.6 K | Ubs Group Ag | 2024-12-31 | 85.2 K | Goldman Sachs Group Inc | 2024-12-31 | 80.3 K | Charles Schwab Investment Management Inc | 2024-12-31 | 63 K | Deutsche Bank Ag | 2024-12-31 | 54.8 K | Bank Of New York Mellon Corp | 2024-12-31 | 50.7 K | Citigroup Inc | 2024-12-31 | 48.8 K | Blue Water Life Science Advisors, Llc | 2024-12-31 | 4.7 M | Blackrock Inc | 2024-12-31 | 1.6 M |
Akoya Biosciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Akoya Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Akoya Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Akoya Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Akoya Biosciences Outstanding Bonds
Akoya Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Akoya Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Akoya bonds can be classified according to their maturity, which is the date when Akoya Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Akoya Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Akoya Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Akoya Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Akoya Biosciences Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akoya Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For information on how to trade Akoya Stock refer to our How to Trade Akoya Stock guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akoya Biosciences. If investors know Akoya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akoya Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.16) | Revenue Per Share | Quarterly Revenue Growth (0.19) | Return On Assets | Return On Equity |
The market value of Akoya Biosciences is measured differently than its book value, which is the value of Akoya that is recorded on the company's balance sheet. Investors also form their own opinion of Akoya Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Akoya Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akoya Biosciences' market value can be influenced by many factors that don't directly affect Akoya Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akoya Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akoya Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akoya Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.